Ludwig In the News

December 8, 2014
American Society of Cell Biology TV

The San Diego Branch focuses mainly on cancer genetics, cell signaling, gene regulation and the mechanisms of cell division. We have made important achievements investigating the processes that cells use to maintain the integrity of their genome, and how failure in these processes can lead to cancer.

November 19, 2014
NBC News

Lab mice are tried-and-true stand-ins for human experimental subjects when it comes to medical studies, but sometimes what works for mice doesn’t work for men and women. Now a comparative survey of mouse and human genomes is taking a huge step toward figuring out why.

October 16, 2014
AACR Cancer Research Catalyst

The National Cancer Institute and other agencies are funding prevention research. But efforts are nowhere near where they ought to be given the approaching tsunami of aging citizens. The bulk of cancer research funding from both public and private sources continues to focus on the treatment of cancer, not its prevention

September 12, 2014
TEDX Cambridge

Just like in life, there are no turn-by-turn directions when it comes to cancer research. Ludwig’s Tyler Jacks shares the lessons he’s learned, and what they mean for all of us.

August 31, 2014
Herald Sun

Victorian Suzanne Reynolds, who had melanoma in her brain, sinus, bone and gallbladder, went into an incredibly rare ‘spontaneous remission’ where her own immune system fired up and killed the cancer. Now, more than a decade later, there are drugs that replicate this astonishing occurrence in a revolutionary new approach to cancer treatment called immunotherapy.

August 25, 2014
Oncology Times

Philip A. Pizzo, MD, the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at the Stanford University School of Medicine, has joined the Board of Directors of the Ludwig Institute for Cancer Research.

August 5, 2014

Ludwig Cancer Research recently announced plans to explore three monoclonal antibodies aimed at two different checkpoint modulators. The term encompasses antibodies devised to block receptors that inhibit the immune response against cancer as well as those that bind and activate receptors known to have the opposite effect.

July 24, 2014
Oncology News

How Daniel K Ludwig’s formula for success has fuelled four decades – and counting – of top-notch cancer research.

July 21, 2014
TEDX Times Square

Ludwig MSK’s Jedd Wolchok speaks on the latest developments in cancer immunotherapy.

April 23, 2014
Scientific American

By releasing the brakes that tumor cells place on the immune system, researchers are developing a new generation of more powerful treatments against malignancy.

April 10, 2014
The Chronicle of Philanthropy

Government funding, which has long supported the bulk of basic scientific research, is increasingly threatened in the U.S. If we hope to capitalize on the remarkable progress made in molecular medicine over the past few decades to solve such intractable problems as cancer, diabetes, and other diseases, something will have to change—and soon.

March 24, 2014
Huffington Post

American science is increasingly starved of funds. In 2013, the U.S. National Institutes of Health was forced to slash $1.5 billion from its budget. As a consequence, only one in seven biomedical researchers who apply for an NIH grant today will receive one — marking an historic low.

March 10, 2014
Bioprocess Online

Ludwig Cancer Research and Agenus Inc. announced that the companies are advancing three selected monoclonal antibody checkpoint modulators (CPMs) into preclinical development.

February 10, 2014
WTTW-TV Chicago Tonight

University of Chicago cancer specialists make strides in curing metastatic cancers.

January 25, 2014
The Lancet

This month, Daniel Ludwig’s trust made a final US$540 million donation to the six American Ludwig Centers he had helped to found. In total, Ludwig has given over $900 million to the six centres.

January 9, 2014
Nonprofit quarterly

In the case of these six cancer research centers, a $540 million endowment is meant to help them pursue work that is speculative and risky, unencumbered by the profit requirements of “the market” or the conservatism and restrictions of government funding.

January 7, 2014
The Scientist

Six U.S. medical centers will each receive $90 million to pursue cancer research with very few strings attached.

January 6, 2014
Chronicle of Philanthropy

Six facilities for cancer studies launched in 2006 by New York-based charity Ludwig Cancer Research will each receive $90-million more from the parent group to pursue unrestricted research into how the disease starts, spreads, and can be stopped.

January 6, 2014

The estate of the late American shipping magnate Daniel Ludwig on Monday donated a total of $540 million to six elite U.S. cancer research facilities, making one of the largest one-time gifts dedicated to combating the disease.

January 6, 2014
Boston Globe

An American shipping magnate’s trust will announce on Monday one of the largest philanthropic gifts to support cancer research: more than half a billion dollars to be divided equally among six institutions, including Harvard Medical School and the Massachusetts Institute of Technology.

January 6, 2014
The Mercury News

Stanford has received a vast sum of money to study a tiny population of deadly cancer cells, a gift that could help combat the heartbreak of phoenixlike disease recurrence.

January 6, 2014
Chicago Tribune

Gift from Ludwig Cancer Research fund comes as government, private grants have declined.

January 6, 2014
USA Today

The Ludwig Cancer Research organization announces one of the largest gifts ever toward cancer research with $540 million to six research centers across the country.

January 6, 2014
The Baltimore Sun

Johns Hopkins University scientists will share in one of the largest one-time philanthropic gifts for cancer research ever made, $540 million aimed at preventing and curing the disease, officials are scheduled to announce today.

January 6, 2014
Boston Magazine

MIT and Harvard each received $90 million from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, which will provide funding to transform basic research on metastasis, the process by which cancer cells spread from a primary tumor to distant sites in the body.

January 6, 2014

A trust fund created by billionaire shipping tycoon Daniel K. Ludwig ends today with a bang and a gift to research. Six U.S. medical centers will receive $540 million—$90 million each—from the fund to endow cancer studies in perpetuity.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?